{"entity":{"id":"nct06037655","kind":"trial","name":"Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC","aka":["Modified"],"tldr":"A phase 2 trial of adebrelimab in gallbladder cancer and other biliary tract cancers, run by The First Affiliated Hospital with Nanjing Medical University, not yet recruiting.","summary":"Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC is a phase 2 interventional study registered as NCT06037655 by The First Affiliated Hospital with Nanjing Medical University, with a registry enrolment figure of 30 participants, started 2023-09-25 and due to reach its primary completion in 2026-03-31. Interventions recorded: Total Neoadjuvant Treatment. Conditions listed: Biliary Tract Neoplasms. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06037655","url":"https://clinicaltrials.gov/study/NCT06037655"}],"tags":["ctgov-ingest","gallbladder-deep-dive"],"related":[],"cancers":["gallbladder","cholangiocarcinoma","biliary-tract-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["adebrelimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06037655","phase":"2","setting":"Gemcitabine/Cisplatin Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable Biliary Tract Carcinoma, A Single-arm Study","sponsor":"The First Affiliated Hospital with Nanjing Medical University","participation":[{"nct":"NCT06037655","source":"https://clinicaltrials.gov/study/NCT06037655","fetchedAt":"2026-10-07T16:54:07.437Z","studySha256":"5d272ec0f250bd225293f83cd7913b7a531ac64a0baf3099b5c0a0a88fd90840","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2023-09-14","leadSponsor":"The First Affiliated Hospital with Nanjing Medical University","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":30,"enrolmentType":"ESTIMATED","siteCount":0,"recruitingSiteCount":0}],"started":"2023-09-25","startedType":"estimated","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06037655/","neighbours":{"cancer":[{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/"},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"}],"term":[{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/"}]}}